Formulation and Stability of Cytokine Therapeutics

被引:62
作者
Lipiainen, Tiina [1 ]
Peltoniemi, Marikki [1 ]
Sarkhel, Sanjay [1 ]
Yrjonen, Teijo [1 ]
Vuorela, Heikki [1 ]
Urtti, Arto [1 ,2 ]
Juppo, Anne [1 ]
机构
[1] Univ Helsinki, Fac Pharm, FIN-00014 Helsinki, Finland
[2] Univ Eastern Finland, Sch Pharm, Kuopio, Finland
关键词
biopharmaceuticals characterization; biosimilar; excipients; injectables; lyophilization; oxidation; protein aggregation; protein formulation; protein structure; solid state; COLONY-STIMULATING FACTOR; HUMAN INTERFERON-BETA; RECOMBINANT HUMAN INTERFERON-ALPHA-2B; TRANSFORM INFRARED-SPECTROSCOPY; SITE-DIRECTED MUTAGENESIS; HUMAN INTERLEUKIN-2; STRUCTURAL-CHARACTERIZATION; CHEMICAL-MODIFICATION; POLYETHYLENE-GLYCOL; BIOLOGICAL-ACTIVITY;
D O I
10.1002/jps.24243
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cytokines are messenger proteins that regulate the proliferation and differentiation of cells and control immune responses. Interferons, interleukins, and growth factors have applications in cancer, autoimmune, and viral disease treatment. The cytokines are susceptible to chemical and physical instability. This article reviews the structure and stability issues of clinically used cytokines, as well as formulation strategies for improved stability. Some general aspects for identifying most probable stability concerns, selecting excipients, and developing stable cytokine formulations are presented. The vast group of cytokines offers possibilities for new biopharmaceuticals. The formulation approaches of the current cytokine products could facilitate development of new biopharmaceuticals. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:307-326, 2015
引用
收藏
页码:307 / 326
页数:20
相关论文
共 140 条
[1]  
Adam VR, 1999, J ONCOL PHARM PRACT, V5, P117
[2]   NATURAL HUMAN INTERFERON-ALPHA-2 IS O-GLYCOSYLATED [J].
ADOLF, GR ;
KALSNER, I ;
AHORN, H ;
MAURERFOGY, I ;
CANTELL, K .
BIOCHEMICAL JOURNAL, 1991, 276 :511-518
[3]  
[Anonymous], 2014, LONQ PROD INF
[4]  
[Anonymous], 2014, DAT FDA APPR DRUG PR
[5]  
[Anonymous], 1998, GRAN LEN DAT SHEET
[6]  
[Anonymous], 2011, ONT DEN DIFTT LAB
[7]  
[Anonymous], 2009, NEUM OPR LAB
[8]  
[Anonymous], 2011, PROL ALD LAB
[9]  
[Anonymous], 2014, INF MED PROD
[10]   ACID UNFOLDING AND SELF-ASSOCIATION OF RECOMBINANT ESCHERICHIA-COLI DERIVED HUMAN INTERFERON-GAMMA [J].
ARAKAWA, T ;
HSU, YR ;
YPHANTIS, DA .
BIOCHEMISTRY, 1987, 26 (17) :5428-5432